SCHEDULE: Armistice Capital Reports 4.99% Stake in BIO-KEY

Armistice Capital and Steven Boyd have filed an amended Schedule 13G, disclosing a 4.99% beneficial ownership stake in BIO-KEY International Inc. as of June 30, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the Reporting Persons, have filed an Amendment No. 1 to Schedule 13G.
• The filing reports beneficial ownership of 359,703 shares of BIO-KEY International Inc. Common Stock.
• This represents 4.99% of the issuer's class of securities.
• The shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital, LLC acting as the investment manager and exercising shared voting and dispositive power.
• Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.
• The reported ownership is as of June 30, 2025.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or outlook. It simply reports an investment stake.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or operations.

Industry Context

This filing indicates a passive investment stake by Armistice Capital, an investment firm, in BIO-KEY International Inc. Such filings are routine disclosures of institutional ownership and do not typically reflect broader industry trends beyond the specific investment decision.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, potentially signaling investor interest in the company.

Key Dates

Keywords

BIO-KEY International Inc., Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing